First Time Identified: The Packaging Process that Makes Viruses Infectious from Common Colds to Polio

Professor Peter Stockley, former Director of the Astbury Centre for Structural Molecular Biology at Leeds, who part supervised the research with Professor Reidun Twarock from York, said: “This study is extremely important because of the way it shifts our thinking about how we can control some viral diseases. If we can disrupt the mechanism of virion formation, then there is the potential to stop an infection in its tracks.

“Our analysis suggests that the molecular features that control the process of virion formation are genetically conserved, meaning they do not mutate easily – reducing the risk that the virus could change and make any new drugs ineffective.” 

The research at Leeds and York brings together experts in the molecular structure of viruses, electron microscopy and mathematical biology.  

The study focuses on a harmless bovine virus that is non-infectious in people, enterovirus-E, which is the universally adopted surrogate for the poliovirus. The poliovirus is a dangerous virus that infects people, causing polio and is the target of a virus eradication initiative by the World Health Organization. 

The enterovirus group also includes the human rhinovirus, which causes the common cold. 

The study published today details the role of what are called RNA packaging signals, short regions of the RNA molecule which together with proteins from the virus’s casing ensure accurate and efficient formation of an infectious virion. 

Using a combination of molecular and mathematical biology, the researchers were able to identify possible sites on the RNA molecule that could act as packaging signals. Using advanced electron microscopes at the Astbury Biostructure Laboratory at the University of Leeds, scientists were able to directly visualize this process – the first time that has been possible with any virus of this type.

Professor Twarock added: “Understanding in detail how this process works, and the fact that it appears conserved in an entire family of viral pathogens, will enable the pharmaceutical industry to develop anti-viral agents that can block these key interactions and prevent disease.”

The work was funded by the Wellcome Trust, the Engineering and Physical Sciences Research Council (EPSRC) and the British Medical Foundation for Medical Research.

Contacts and sources: